Anti-Migratory and Cytotoxic Activities of [Ga(8-hydroxyquinolinato)3]: Roles of Endogenous Cu(II) and Drug-Induced Phenotypic Changes

As shown by IncuCyte Zoom imaging proliferation assays, invasive triple-negative human breast MDA-MB-231 cancer cells treated with sub-toxic doses (5.0-20 μM, 72 h) of [GaQ3] (Q = 8-hydroxyquinolinato) caused profound morphological changes and inhibition of cell migration, which were likely due to t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chemistry : a European journal 2023-09, Vol.29 (54), p.e202203323-e202203323
Hauptverfasser: Kuramarohit, Serene, Yaourtis, Andria M, Nguyen, Annie, Wood, Michelle L, Levina, Aviva, Lay, Peter Andrew
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:As shown by IncuCyte Zoom imaging proliferation assays, invasive triple-negative human breast MDA-MB-231 cancer cells treated with sub-toxic doses (5.0-20 μM, 72 h) of [GaQ3] (Q = 8-hydroxyquinolinato) caused profound morphological changes and inhibition of cell migration, which were likely due to terminal cell differentiation or similar phenotypical change. This is the first demonstration of potential use of a metal complex in differentiation anti-cancer therapy. Additionally, a trace amount of Cu(II) (0.20 μM) added to the medium dramatically increased [GaQ3] cytotoxicity (IC50 ~ 2 μM, 72 h) due to its partial dissociation and the action of the HQ ligand as a Cu(II) ionophore, as shown with electrospray mass spectrometry and fluorescence spectroscopy assays in the medium. Hence, cytotoxicity of [GaQ3] is strongly linked to ligand binding of essential metal ions in the medium, e.g., Cu(II). Appropriate delivery mechanisms of such complexes and their ligands could enable a powerful new triple therapeutic approach for cancer chemotherapy, including cytotoxicity against primary tumour, arrest of metastases, and activation of innate and adaptive immune responses.
ISSN:0947-6539
1521-3765
DOI:10.1002/chem.202203323